drugs-final Flashcards Preview

Drugs and Disease > drugs-final > Flashcards

Flashcards in drugs-final Deck (37):
1

type of drug of low efficacy

partial agonist

2

rate of drug action depends on what

absorption

distribution

3

duration and intensity of drug depends on what

metabolism

4

type of reactions in phase 1 metabolism

oxidation

hydrolysis

5

phase 1 metabolism does what

increase functionality

increase polarity

increase water solubility

6

phase 2 metabolism does what

increases size

increase polarity

increase water solubility

7

MOA: inhibit prostaglandin synthesis

inhibit COX enzymes

NSAIDs - salicylates

aspirin, diflunisal, ibuprofen, naproxen

8

• MOA – inhibits liberation of arachidonic acid from cellular membrane by indirectly inhibiting phospholipase A2. Also inhibit
• Steroid moves through cell membrane and binds to receptor → go pass nuclear membrane → DNA → modify gene expression → lipocortins (annekins) → annekins inhibit PLA2 at the cell membrane

glucocorticoids

anti-inflammatories

9

SAARDs

slow acting anti-rheumatic drugs

anti-inflammatory

10

M-antagonist

bronchodilator - symptomatic relief for asthma

11

terbutaline
albuterol
pirbuterol

B2 agonist - symptom relief for asthma

12

methylxanthines-theophylline

bronchodilator for asthma

13

release inhibitor: inhibit early/late phase allergic response that leads to bronchoconstriction

anti-inflammatory
- asthma

cromolyn sodium
nedocromil sodium

14

lypoxygenase inhibitor - Xileuton

LT receptor agonists - zafirlukast

leukotriene modifiers

anti-inflammatory for asthma

15

o Reduce fat (re)absorption from intestine

bile acid-binding resins

16

o MOA: resins (amine) bind to carboxylic acids (de-protonated and negatively charged); resins prevent reabsorption of bile acids

bile acid-binding resins

17

o MOA: competitive inhibitors of HMG-CoA reductase

reduces cholesterol

modifies hepatic synthesis of lipoproteins

statins

18

reduces secretion of VLDL from liver

modify release of hepatic lipoproteins

Niacin

19

o MOA – reduce VLDL and increase HDL; agonize PPAR; increase peripheral clearance of lipoproteins

fabric acid derivatives

"-fibr"

20

adjunct to statins

lowers LDL; inhibits dietary cholesterol absorption

ezetimibe

21

• MOA – inhibits DOPA decarboxylase in PNS

carbidopa

Parkinson's

22

Bromocriptine
Pergolide
Pramipexole
Ropinirole

Parkinsons

Dopamine agonists

23

• MOA – alter DA uptake/release; acts on glutamate NMDA receptors

amantadine

Parkinson's

24

• MOA – inhibits MAO-B (breaks down DA)

selegiline

parkinson's

25



trihexyphenidyl
benzatropine mesylate
diphenhydramine

parkinson's

muscarinic antagonists

26

Tetrabenazine - DA depleting

Haloperidol - D2 antagonists

Carbamazepine - anti epileptics

Huntingtons

27

tacrine
donepezil
rivastigmine
galantamine

AChE inhibitors

alzheimer's

28

• MOA – inhibit effect of glutamate and excessive neuronal stimulation

NMDA receptor blocker

alzheimers

29

• MOA – bind to GABA-BZD-picrotoxin multi-subunit receptor/Cl- ion channel (inhibitory) → increase Cl- ion conductance through the channel complex into neurons (hyperpolarize) → enhance activity of GABA → inhibitors CNS function

benzodiazepines

anxiolytics

30

serotonin 5-HT1A receptor agonists

anxiolytics

31

buspirone

• MOA – partial agonists at 5 HT1A site and weak affinity for DA receptor as antagonist; no affinity for BZD/GABA sites

anxiolytic

BZD alternative

32

• MOA – prevent breaks down of 5-HT, DA, and NE

• Iproniazid, isoniazid

MAO inhibitors

antidepressant

33

• MOA – prevent reuptake of monoamines by inhibiting monoamine transporters

• Imipramine, amitriptyline and doxepin (NE and 5-HT)

TCA's

antidepressant

34

• MOA – inhibit uptake of 5-HT into neurons by blocking serotonin transporter

• Fluoxetine, fluvoxamine

SSRI's

antidepressant

35

• Carbamazepine
• Phenytoin

partial and general tonic-clonic

o MOA: inactivate voltage-activated, NA+ channels → inhibit sustained firing of neurons

36

phenobarbital and vigabatrin

partial and general tonic-clonic

enhance GABA activity

37

ethosuximide

valproate

generalized seizures

limit activation of T-current, voltage activated Ca2+ channel